Erratum: Interaction of selective serotonin reuptake inhibitors with neuronal nicotinic acetylcholine receptors (Biochemistry (2010) 49 (5734) DOI: 10.1021/bi100536t);Interaction of selective serotonin reuptake inhibitors with neuronal nicotinic acetylcholine receptors

Biochemistry

Volumn 49, Issue 27, 2010, Pages 5734-5742

  Arias, Hugo R ^a   Feuerbach, Dominik ^b   Targowska Duda, Katarzyna M ^c   Russell, Megan ^a   Jozwiak, Krzysztof ^c  

^a MIDWESTERN UNIVERSITY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; CHEMISTRY;

BINDING AFFINITIES; CONFORMATIONAL STATE; DESENSITIZED STATE; MOLECULAR DOCKING; NICOTINIC ACETYLCHOLINE RECEPTORS; RADIOLIGAND BINDING; SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS; TRICYCLIC ANTIDEPRESSANTS;

BINDING ENERGY;

CALCIUM ION; FLUOXETINE; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA3BETA4; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA7; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; PAROXETINE; UNCLASSIFIED DRUG; CHOLINERGIC RECEPTOR; IMIPRAMINE; ION CHANNEL; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; BINDING AFFINITY; CALCIUM TRANSPORT; CELL STRAIN HEK293; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; LIGAND BINDING; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECEPTOR AFFINITY; CHEMISTRY; CONFORMATION; METABOLISM; NERVE CELL;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; FLUOXETINE; HUMANS; IMIPRAMINE; ION CHANNELS; MOLECULAR CONFORMATION; NEURONS; PAROXETINE; RECEPTORS, CHOLINERGIC; RECEPTORS, NICOTINIC; SEROTONIN UPTAKE INHIBITORS;

EID: 77954753254     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi101088a     Document Type: Erratum

References (42)

1. National Institute of Mental Health (2008) Depression. Publication 08 3561, pp 1-25 (www.nimh.nih.gov).
2. Levinson, D. F. (2006) The genetics of depression: A review. Biol. Psychiatry 60, 84-92.
3. Peterson, B. S., Warner, V., Bansal, R., Zhu, H., Hao, X., Liu, J., Durkin, K., Adams, P. B., Wickramaratne, P., and Weissman, M. M. (2009) Cortical thinning in persons at increased familial risk for major depression. Proc. Natl. Acad. Sci. U.S.A. 106, 6273-6278.
4. Baldessarini, R. J. (2001) Drugs and the treatment of psychiatric disorders. In Goodman & Gilman's The pharmacological basis of therapeutics (Hardman, J. G., and Limbird, L. E., Eds.) 10th ed., pp 447-483, McGraw-Hill, New York.
5. García-Colunga, J., Awad, J. N., and Miledi, R. (1997) Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc. Natl. Acad. Sci. U.S.A. 94, 2041-2042.
6. García-Colunga, J., Vázquez-Gómez, E., and Miledi, R. (2004) Combined actions of zinc and fluoxetine on nicotinic acetylcholine receptors. Pharmacogenomics J. 4, 388-393.
7. García-Colunga, J., and Miledi, R. (1999) Blockage of mouse muscle nicotinic receptors by serotonergic compounds. Exp. Physiol. 84, 847-864.
8. López-Valdés, H. E., and García-Colunga, J. (2001) Antagonism of nicotinic acetylcholine receptors by inhibitors of monoamine uptake. Mol. Psychiatry 6, 511-519.
9. Maggi, L., Palma, E., Miledi, R., and Eusebi, F. (1998) Effects of fluoxetine on wild and mutant neuronal R7 nicotinic receptors. Mol. Psychiatry 3, 350-355.
10. Fryer, J. D., and Lukas, R. J. (1999) Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function. J. Neurochem. 72, 1117-1124.
11. Feuerbach, D., Lingenhöhl, K., Dobbins, P., Mosbacher, J., Corbett, N., Nozulak, J., and Hoyer, D. (2005) Coupling of human nicotinic acetylcholine receptors R7 to calcium channels in GH3 cells. Neuropharmacology 48, 215-227.
12. Arias, H. R., Feuerbach, D., Bhumireddy, P., and Ortells, M. O. (2010) Inhibitory mechanisms and binding site locations for serotonin selective reuptake inhibitors on nicotinic acetylcholine receptors. Int. J. Biochem. Cell Biol. 42, 712-724.
13. Arias, H. R., Bhumireddy, P., and Bouzat, C. (2006) Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors. Int. J. Biochem. Cell Biol. 38, 1254-1276.
14. Arias, H. R. (2006) Ligand-gated ion channel receptor superfamilies. In Biological and Biophysical Aspects of Ligand-Gated Ion Channel Receptor Superfamilies (Arias, H. R., Ed.) pp 1-25, Research Signpost, Kerala, India.
15. Albuquerque, E. X., Pereira, E. F. R., Alkondon, A., and Rogers, S. W. (2009) Mammalian nicotinic acetylcholine receptors: From structure to function. Physiol. Rev. 89, 73-120.
16. Arias, H. R. (2009) Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions? Int. J. Biochem. Cell Biol. 41, 2098-2108.
17. Shytle, R. D., Silver, A. A., Lukas, R. J., Newman, M. B., Sheehan, D. V., and Sanberg, P. R. (2002) Nicotinic receptors as targets for antidepressants. Mol. Psychiatry 7, 525-535.
18. Picciotto, M. R., Brunzell, D. H., and Caldarone, B. J. (2002) Effect of nicotine and nicotinic receptors on anxiety and depression. NeuroReport 13, 1097-1106.
19. George, T. P., Sacco, K. A., Vessicchio, J. C., Weinberger, A. H., and Shytle, R. D. (2008) Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder. A preliminary study. J. Clin. Psychopharmacol. 28, 340-344.
20. Popik, P., Kozela, E., and Krawczyk, M. (2003) Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram.Br.J. Pharmacol. 139, 1196-1202.
21. Caldarone, B. J., Hrrist, A., Cleary, M. A., Beech, R. D., King, S. L., and Picciotto,M. R. (2004) High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. Biol. Psychiatry 56, 657-664.
22. Polson, R. G., Fleming, P. M., and O'shea, J. K. (2004) Fluoxetine in the treatment of amphetamine dependence. Hum. Psychopharmacol. Clin. Exp. 8, 55-58.
23. Michelmore, S., Croskery, K., Nozulak, J., Hoyer, D., Longato, R., Weber, A., Bouhelal, R., and Feuerbach, D. (2002) Study of the calcium dynamics of the human α4β2, α3β4 and α1β1γδ nicotinic acetylcholine receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 366, 235-245.
24. Arias,H. R., Targowska-Duda, K. M., Sullivan, C. J., Feuerbach, D., Maciejewski, R., and Jozwiak, K. (2010) Different interaction between tricyclic antidepressants and mecamylamine with the human α3β4 nicotinic acetylcholine receptor. Int. Neurochem. 56, 642-649.
25. Arias, H. R., Rosenberg, A., Targowska-Duda, K. M., Feuerbach, D., Jozwiak, K., Moaddel, R., and Weiner, I. W. (2010) Tricyclic antidepressants and mecamylamine bind to different sites in the human α4β2 nicotinic receptor ion channel. Int. J. Biochem. Cell Biol. 42, 1007-1018.
26. Arias, H. R., Gumilar, F., Rosenberg, A., Targowska-Duda, K. M., Feuerbach, D., Jozwiak, K., Moaddel, R., Wainer, I. W., and Bouzat, C. (2009) Interaction of bupropion with muscle-type nicotinic acetylcholine receptors in different conformational states. Biochemistry 48, 4506-4518.
27. Moore, M. A., and McCarthy, M. P. (1995) Snake venom toxins, unlike smaller antagonists, appear to stabilize a resting state conformation of the nicotinic acetylcholine receptor. Biochim. Biophys. Acta 1235, 336-342.
28. Cheng, Y., and Prusoff, W. H. (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108.
29. Sanghvi, M., Hamouda, A. K., Jozwiak, K., Blanton, M. P., Trudell, J. R., and Arias, H. R. (2008) Identifying the binding site(s) for antidepressants on the Torpedo nicotinic acetylcholine receptor: [3H]2-Azidoimipramine photolabeling and molecular dynamics studies. Biochim. Biophys. Acta 1778, 2690-2699.
30. Unwin, N. (2005) Refined structure of the nicotinic acetylcholine receptor at 4 Å resolution. J. Mol. Biol. 346, 967-989.
31. Miyazawa, A., Fujiyoshi, Y., and Unwin, N. (2003) Structure and gating mechanism of the acetylcholine receptor pore. Nature 423, 949-955.
32. Gerzanich, V., Peng, X., Wang, F., Wells, G., Anand, R., Fletcher, S., and Lindstrom, J. (1995) Comparative pharmacology of epibatidine: A potent agonist for neuronal nicotinic acetylcholine receptors. Mol. Pharmacol. 48, 774-782.
33. DeVane, C. L. (1999) Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell. Mol. Neurobiol. 19, 443-466.
34. Karson, C. N., Newton, J. E., Livingston, R., Jolly, J. B., Cooper, T. B., Sprigg, J., and Komoroski, R. A. (1993) Human brain fluoxetine concentrations. J. Neuropsychiatry Clin. Neurosci. 5, 322-329.
35. Bolo, N. R., Hodé, Y., Nédélec, J., Lainé, E., Wagner, G., and Macher, J. (2000) Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23, 428-438.
36. Glick, S. D., Sell, E. M., and Maisonneuve, I. M. (2008) Brain regions mediating α3β4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration. Eur. J. Pharmacol. 599, 91-95.
37. Grady, S. R., Moretti, M., Zoli, M., Marks, M. J., Zanardi, A., Pucci, L., Clementi, F., and Gotti, C. (2009) Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the α3β4* and α3β3β4* subtypes mediate acetylcholine release. J. Neurosci. 29, 2272-2282.
38. Gotti, C., Zoli, M., and Clementi, F. (2006) Brain nicotinic acetylcholine receptors: Native subtypes and their relevance. Trends Pharmacol. Sci. 27, 482-491.
39. DeBiasi, M., and Salas, R. (2008) Influence of neuronal nicotinic receptors over nicotine addiction and withdrawal. Exp. Biol. Med. 233, 917-929.
40. Gumilar, F., Arias, H. R., Spitzmaul, G., and Bouzat, C. (2003) Molecular mechanism of inhibition of nicotinic acetylcholine receptors by tricyclic antidepressants.Neuropharmacology 45, 964-976.
41. Hamouda,A.K., Chiara,D. C., Blanton, M. P., and Cohen, J. B. (2008) Probing the structure of the affinity-purified and lipid-reconstituted Torpedo nicotinic acetylcholine receptor. Biochemistry 47, 12787-12794.
42. Gumilar, F., and Bouzat, C. (2008) Tricyclic antidepressants inhibit homomeric Cys-loop receptors by acting at different conformational states. Eur. J. Pharmacol. 584, 30-39.